Voyager Therapeutics reported its tau-silencing gene therapy VY1706 was well-tolerated and reduced tau in preclinical data, paving the way for human trials in the second half of 2026.
Back
Voyager Surges After Positive 3-Month Alzheimer's Gene Therapy Data
Voyager Therapeutics Inc. (Nasdaq: VYGR) presented positive three-month toxicology data for its Alzheimer's gene therapy candidate, VY1706, signaling a clear path to begin human trials later this year. The results, unveiled at the American Society of Gene & Cell Therapy annual meeting, showed a single intravenous dose was well-tolerated and successfully reduced tau protein levels in non-human primates, a key step in developing treatments for the neurodegenerative disease.
"As the ‘Year of Tau’ for Alzheimer’s disease continues to unfold, Voyager looks forward to third-party data in mid-2026 that have the potential to confirm tau knockdown as the next critical approach to treating Alzheimer’s disease," said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. "Then, in the second half of the year, we expect first-in-human dosing of our tau silencing gene therapy VY1706."
The company confirmed it is on track to submit an Investigational New Drug (IND) application to the FDA in the second quarter of 2026, with clinical trials for VY1706 expected to commence in the second half of the year. The therapy is derived from Voyager's TRACER AAV capsid discovery platform, which is designed to enable high brain penetration for genetic medicines following intravenous dosing.
The positive preclinical data significantly de-risks the VY1706 program and strengthens Voyager's position in the competitive field of Alzheimer's research. For investors, the announcement provides a clear clinical timeline for a lead asset, backed by a solid financial foundation. The company ended the first quarter of 2026 with $172 million in cash, which it projects will provide financial runway into 2028, funding operations through multiple potential clinical milestones.
The Crowded Field of Tau Therapies
Voyager's progress comes as multiple companies race to develop effective treatments targeting the tau protein, which forms toxic tangles in the brains of Alzheimer's patients. While the initial wave of Alzheimer's drugs, like those from Eisai and Eli Lilly, have focused on amyloid plaques, many researchers believe targeting tau is the next crucial step. Voyager's gene therapy approach, which aims to silence the production of the tau protein, represents a different modality from the antibody-based treatments currently in development by competitors like Johnson & Johnson and Biogen. The upcoming third-party data on other tau-targeting agents in mid-2026, mentioned by Dr. Sandrock, will be a key barometer for the entire field.
Financials and Broader Pipeline
While advancing its Alzheimer's program, Voyager is also managing its finances and progressing a broader pipeline. The company reported a net loss of $27.9 million, or $0.47 per share, for the first quarter of 2026, a narrower loss than the $31.0 million reported for the same period in 2025. Collaboration revenue was $2.6 million. Beyond Alzheimer's, Voyager's pipeline includes programs for Friedreich’s ataxia, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS), many of which leverage its TRACER platform and are being advanced in partnership with major pharmaceutical firms including Novartis and Neurocrine Biosciences.
This article is for informational purposes only and does not constitute investment advice.
[1] Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026[2] Voyager Therapeutics (VYGR) reports Q1 loss, misses revenue estimates[3] Krystal Biotech: Vyjuvek Is Not The Primary Asset[4] Voyager Reports First Quarter 2026 Financial and Operating Results[5] Krystal Biotech: A Q1 Earnings Beat With Multiple Catalysts In 2026 And 2027
